The new study, published in the British Journal of Cancer, focuses on a kinase called ATR, short for ataxia telangiectasia and Rad3-related protein. ATR sits at the heart of the cellular response to replication stress, the potentially lethal situation in which the molecular machinery that copies DNA stalls or breaks down. When chemotherapy drugs such as mitomycin C damage DNA, dividing cells rely heavily on ATR signalling to pause the cell cycle, stabilise stalled replication forks and coordinate repair. Block ATR pharmacologically, and cells exposed to DNA-damaging agents lose their safety net: replication forks collapse, DNA double-strand breaks accumulate, and the cell is pushed toward catastrophe. This concept, often described as exploiting a vulnerability created by the tumour’s own dependence on DNA damage checkpoints, has already shown promise in clinical trials of ATR inhibitors such as berzosertib in combination with platinum chemotherapy for advanced solid tumours.

What makes the Utrecht study distinctive is its model system. Rather than relying on immortalised cancer cell lines grown in two dimensions, which often fail to capture the biology of real tumours, the team used patient-derived organoids, miniature three-dimensional tumour cultures grown from tissue of six patients with non-muscle invasive bladder cancer. Organoids preserve many of the genetic and molecular features of the original tumours, including the expression of urothelial carcinoma markers, making them a far more faithful testing ground for new drug combinations. The researchers confirmed that their organoid lines expressed characteristic bladder cancer markers, validating them as genuine representatives of the disease they were designed to model.

The experimental design cleverly mimicked clinical practice. In patients, mitomycin C is delivered directly into the bladder as an instillation that remains in contact with the tumour tissue for roughly one to two hours before being drained. The researchers therefore exposed the organoids to mitomycin C for just two hours, replicating the transient exposure that tumour cells experience in the bladder, and only afterwards did they add ATR inhibitors, which the cells encountered for a prolonged 72-hour period. Three clinically relevant ATR inhibitors were tested: berzosertib, ceralasertib and tuvusertib, all of which have entered clinical trials in various cancers. The team also examined combinations with gemcitabine and epirubicin, two further agents used in intravesical chemotherapy regimens, in one organoid line.

The results were striking. Organoids treated with mitomycin C alone, or with an ATR inhibitor alone, eventually recovered: when the researchers followed the cultures for six weeks after treatment, the surviving cells proliferated at rates similar to untreated controls, demonstrating that neither agent on its own could eliminate the tumour cell population. In sharp contrast, organoids that received the sequential combination of mitomycin C followed by an ATR inhibitor showed severely impaired viability, and crucially, this effect persisted throughout the six-week observation period. The combination did not merely slow the cancer cells down; it appeared to destroy their capacity to regrow, which is precisely the property needed for a therapy intended to prevent recurrence after tumour resection.

Delving into the mechanism, the researchers showed that berzosertib potently suppressed the ATR signalling that mitomycin C normally triggers. DNA damage induced by the chemotherapy was marked by phosphorylated H2AX, a well-established molecular beacon of DNA double-strand breaks, and blocking ATR prevented the checkpoint response that would normally allow cells to survive this damage. Consistent with catastrophic, irreparable DNA damage, the combination treatment drove the organoid cells into apoptosis, the controlled programme of cell death. Quantitative analysis of the drug interaction using synergy scoring frameworks confirmed that the effect was genuinely synergistic rather than merely additive, meaning the two drugs together killed far more cells than would be predicted from their individual activities.

The implications for patients are considerable. Recurrence after intravesical therapy remains the central clinical challenge in non-muscle invasive bladder cancer, driving repeated surgeries, lifelong surveillance and, in a substantial minority of cases, progression to life-threatening muscle-invasive disease. The economic burden of bladder cancer across Europe is among the highest of any malignancy, largely because of the intensity of monitoring and repeat treatment that recurrence entails. A regimen that converts transient chemotherapy exposure into durable eradication of residual tumour cells could reduce recurrence rates, spare patients repeated interventions and delay or prevent progression. Because ATR inhibitors such as berzosertib, ceralasertib and tuvusertib are already in clinical development, the path from laboratory finding to clinical testing is shorter than for an entirely novel drug class.

There are important caveats. The study is preclinical, conducted in organoids rather than in patients, and although organoids are among the most clinically predictive laboratory models available, they cannot fully reproduce the immune system, the bladder wall architecture or the complex urine environment that shapes drug activity in vivo. The number of organoid lines tested, six for the mitomycin C combinations, is modest, and the gemcitabine and epirubicin experiments were limited to a single line, so the generality of the synergy across the molecular diversity of bladder cancer remains to be established. Questions also remain about the optimal sequencing, dosing and delivery of ATR inhibitors in the bladder, and about whether systemic administration would be needed or whether the inhibitors could themselves be delivered intravesically to limit side effects.

Nevertheless, the study provides a compelling proof of principle that the DNA damage response is a druggable Achilles heel of non-muscle invasive bladder cancer, and it establishes patient-derived organoids as a practical platform for optimising intravesical combination therapies before they are tested in the clinic. The findings build on a growing body of evidence that ATR inhibition sensitises bladder tumours to DNA-targeted agents, including earlier work showing enhanced cisplatin and gemcitabine activity in bladder cancer cell lines and clinical trial data combining berzosertib with platinum chemotherapy in advanced urothelial carcinoma. If the synergy observed in these miniature tumours translates to patients, the humble bladder instillation, a treatment whose basic design has changed little in decades, could be transformed into a precision strike that leaves behind not just damaged cancer cells, but none at all.

Subject of Research: Combining ATR kinase inhibitors with intravesical chemotherapy to prevent recurrence in non-muscle invasive bladder cancer, tested in patient-derived organoids.

Article Title: ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids

Article References: Zuidema, A., Nijland, L., van Megesen, K., Vosjan, M. M., Viergever, B. J., Kranenburg, O., & Meijer, R. P. (2026). ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03581-0

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03581-0

Keywords: bladder cancer, ATR inhibitors, mitomycin C, patient-derived organoids, DNA damage response, non-muscle invasive bladder cancer, berzosertib, ceralasertib, tuvusertib, intravesical chemotherapy, drug synergy, cancer recurrence

The research team, led by Di Liu and Guo Deng of The People’s Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture, together with Hanluo Yang and Qingyu Zhang of Jinping County People’s Hospital, began by asking a basic pharmacological question: how sensitive are bladder cancer cells to trifolirhizin? Using cell counting kit-8 assays on two widely studied human bladder carcinoma cell lines, T24 and UMUC3, they measured the concentration required to kill half of the cells. The answer was strikingly consistent across both lines, with IC50 values of 67.41 micromolar for T24 cells and 72.58 micromolar for UMUC3 cells. Those figures establish trifolirhizin as a genuine cytotoxic agent against these aggressive tumor cells rather than a marginal one, and they provided the dosing foundation for every experiment that followed.

Viability alone, however, tells only part of the story in oncology research. A compound can poison cells without touching the behaviors that actually make cancer dangerous: uncontrolled replication and tissue invasion. To probe these hallmarks, the researchers turned to colony formation assays, which measure the capacity of individual tumor cells to multiply into visible colonies over days and weeks. Trifolirhizin treatment markedly reduced the number of colonies the bladder cancer cells could establish, signaling a direct suppression of long-term proliferative potential. This kind of assay is widely regarded as a stringent test of a drug’s anti-tumor character, because surviving even a brief exposure is not enough; the cells must retain the full machinery for sustained growth, and trifolirhizin appears to compromise exactly that machinery.

Invasion was the next target on the team’s list. Malignant tumors earn their lethal reputation not from where they start but from where they spread, and bladder cancer is no exception. The investigators used transwell migration assays to quantify how many cells could push through a membrane barrier, a standard laboratory proxy for invasive behavior. Trifolirhizin treatment significantly decreased the number of invading cells. Crucially, the molecular correlates of that behavioral shift told a coherent story: levels of vimentin, an intermediate filament protein that supports cellular motility and is a classic marker of epithelial-mesenchymal transition, dropped after treatment, while E-cadherin, an adhesion molecule that helps hold epithelial cells together and restrains migration, increased. In other words, the compound appeared to pull the cells back from a mobile, invasive state toward a more settled, epithelial identity.

Perhaps the most forward-looking dimension of the study concerns immune evasion, the process by which tumors render themselves invisible or hostile to the body’s defensive cells. The researchers found that trifolirhizin-treated bladder cancer cells became more vulnerable to CD8-positive T cell-mediated cytotoxicity, the principal killing mechanism of cellular antitumor immunity. Alongside this, they measured elevated levels of interferon-gamma, a cytokine that serves as both a marker and a driver of an activated antitumor immune response. By quantifying cytokines in the culture environment, the team showed that the compound did not merely make tumor cells more fragile; it also shifted the signaling landscape in ways that favor immune recognition and attack. That dual action, direct toxicity plus immune reactivation, is precisely the profile that modern immunotherapy research seeks to amplify.

With the phenotypic effects established, the study moved to its mechanistic core: the AKT/NF-κB pathway. Protein kinase B, universally abbreviated as AKT, is a kinase that promotes survival and growth in countless cancers, while nuclear factor kappa-B is a transcription factor that switches on genes supporting inflammation, survival, invasion, and immune escape. The two are functionally intertwined, with AKT activity frequently reinforcing NF-κB signaling. Using immunoblotting, the researchers showed that trifolirhizin treatment attenuated the phosphorylation of both proteins, effectively dialing down the pathway’s activity. Because phosphorylation is the molecular switch that activates these signaling proteins, its reduction means the pathway was genuinely silenced, not merely perturbed.

Correlation is not causation, however, and the team designed an elegant validation experiment to close that gap. They co-treated the cells with SC79, a pharmacological activator of AKT that forces the pathway back into gear even in the presence of an upstream inhibitor. The result was decisive. When SC79 was added alongside trifolirhizin, the compound’s effects on proliferation, apoptosis, invasion, and immune escape indicators in T24 cells were substantially reversed. Markers that trifolirhizin had pushed in an antitumor direction drifted back toward their malignant baseline. This rescue experiment provides the strongest form of evidence short of genetic knockout that the AKT/NF-κB axis is not merely one of many targets but the central conduit through which trifolirhizin exerts its anticancer activity in bladder carcinoma cells.

Laboratory dishes are one thing; living tumors are another. To test whether the findings would survive the far more complex environment of an organism, the researchers turned to xenograft models, in which human bladder cancer cells are implanted into mice and allowed to form tumors. Animals treated with trifolirhizin carried a visibly reduced tumor burden compared with untreated controls, confirming that the compound’s cytotoxic and antiproliferative effects translate into slower tumor growth in vivo. Tissue analysis reinforced the cellular findings: hematoxylin and eosin staining, immunohistochemistry, and immunoblotting revealed reduced vimentin expression within the tumors, increased markers of apoptosis, and elevated interferon-gamma levels. Once again, the AKT/NF-κB pathway showed consistently inhibited expression in tumors harvested from trifolirhizin-treated mice, mirroring the in vitro mechanism at the level of intact tissue.

The convergence of these results paints trifolirhizin as a multimodal therapeutic candidate, a phrase the authors themselves use in their conclusion. By suppressing proliferation, blunting invasion, promoting apoptosis, and enhancing immune-mediated killing, all through downregulation of a single druggable signaling pathway, the compound occupies an unusually versatile position for a natural product. Pterocarpan flavonoids of this class have long attracted attention in chemoprevention and anticancer research, but their efficacy and molecular mechanisms in bladder carcinoma had remained unexplored until this study. The work was approved by the ethics committee of The People’s Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture, and the authors declare no competing interests.

Cautious optimism is the appropriate stance. The IC50 values lie in the high micromolar range, and the journey from xenograft mice to human patients involves hurdles of pharmacokinetics, safety, and formulation that no cell culture or animal model can predict. Still, the study’s design, combining functional assays, cytokine quantification, flow cytometry, pathway rescue with a pharmacological activator, and in vivo validation, exemplifies the rigorous architecture that transforms a plant-derived molecule into a credible drug lead. For a disease that continues to challenge urologists with recurrence and immune evasion, trifolirhizin now offers a scientifically grounded reason for excitement, and a clear mechanistic road map for the therapies that may follow it.

The choice of T24 and UMUC3 as experimental platforms deserves brief elaboration, since these cell lines embody distinct molecular subtypes of bladder carcinoma. T24 cells are derived from a transitional cell carcinoma and display a highly aggressive, invasive phenotype, while UMUC3 carries activating mutations in the HRAS oncogene, a lesion that sits squarely upstream of the PI3K/AKT cascade. The fact that trifolirhizin suppressed AKT phosphorylation and produced comparable IC50 values in both lines suggests its activity does not depend on a single driver mutation, a property that would broaden its potential applicability across molecularly diverse tumors.

The immune findings also fit into a larger conceptual shift in oncology. For decades, cytotoxic chemotherapy was viewed as inherently immunosuppressive, but it is now understood that certain agents can provoke immunogenic cell death, releasing tumor antigens and inflammatory signals that recruit cytotoxic T lymphocytes. The observed rise in interferon-gamma and the heightened susceptibility of treated cells to CD8-positive T cell killing are consistent with this paradigm, raising the possibility that trifolirhizin could act synergistically with immune checkpoint inhibitors, though such combinations remain untested in this study.

Methodologically, the use of SC79 as a pathway rescue tool reflects a standard of mechanistic proof increasingly expected in natural product research, where compounds often have many off-target effects. By demonstrating that forced AKT reactivation reverses the drug’s phenotypic effects, the authors substantially narrow the causal interpretation. Nevertheless, the study does not identify the direct molecular target of trifolirhizin upstream of AKT, leaving open whether the compound binds AKT itself, an upstream activator, or some other regulator of the cascade. Future work with target-identification techniques such as affinity pull-down or thermal proteome profiling would help resolve this question and clarify whether the high micromolar potency can be improved through rational chemical optimization of the pterocarpan scaffold.

Subject of Research: The anticancer effects of the natural flavonoid trifolirhizin on bladder carcinoma via modulation of the AKT/NF-κB signaling pathway

Article Title: Trifolirhizin induces apoptosis and suppresses proliferation, invasion and immune evasion in bladder cancer via AKT/NF-κB signaling pathway

Article References: Liu, D., Deng, G., Yang, H., & Zhang, Q. (2026). Trifolirhizin induces apoptosis and suppresses proliferation, invasion and immune evasion in bladder cancer via AKT/NF-κB signaling pathway. BioMedical Engineering OnLine. https://doi.org/10.1186/s12938-026-01613-7

Image Credits: AI Generated

DOI: 10.1186/s12938-026-01613-7

Keywords: bladder cancer, trifolirhizin, apoptosis, AKT/NF-κB pathway, immune evasion, cell proliferation, invasion, vimentin, E-cadherin, CD8-positive T cells, interferon-gamma, xenograft models

Most women who undergo radical cystectomy are in their postmenopausal phase, which somewhat alleviates the concerns relating to the loss of ovarian function. Conversely, there exists a notable demographic of premenopausal women who face the abrupt onset of surgical menopause due to the removal of their ovaries—an essential consideration when planning comprehensive cancer treatment. The consequences of this immediate hormonal change are widespread and can significantly affect a woman’s overall well-being. The abrupt withdrawal of sex steroid hormones from the body precipitates various symptoms such as vasomotor instability, marked by hot flashes, night sweats, and other discomforts that often accompany menopause.

Additionally, the impact of surgical menopause extends beyond the immediate symptoms, encompassing serious long-term health risks. Women who experience surgical menopause face a heightened vulnerability to conditions like osteoporosis, which can lead to fractures and a decline in bone health. This increased risk necessitates vigilant monitoring and proactive approaches to bone health management. Furthermore, the cardiovascular ramifications of losing ovarian function cannot be overlooked, as estrogen plays a key role in maintaining cardiovascular wellness. The abrupt transition into a hormonal landscape devoid of these protective elements can contribute to an escalation in cardiovascular disease incidence among affected women.

Cognitive decline also represents a substantial risk factor associated with surgical menopause. Research suggests that the loss of estrogen may negatively impact cognitive functions, increasing the likelihood of conditions such as dementia over time. For women facing cancer treatment, the prospect of these later-life challenges presents a dual burden: managing an aggressive cancer while simultaneously grappling with the realities of sudden menopause. Thus, it becomes critical for urologists and healthcare providers to adopt a holistic view of the care they provide, comprehensively addressing both oncological needs and the potential for diminished quality of life through effective communication and management strategies.

While the benefits of ovarian preservation during radical cystectomy are becoming more recognized within the medical community, some premenopausal patients may still require oophorectomy for oncological reasons. The decision to remove the ovaries must be made judiciously, balancing the need for cancer control with the long-term implications for the patient’s health and well-being. This nuanced approach necessitates a thorough discussion between the healthcare provider and the patient, ensuring that the patient is well-informed about the potential consequences of their surgical choices.

However, the reality is that many urologists may not be fully aware or adequately trained in the management of surgical menopause and its associated complications. This lack of awareness can lead to a troubling gap in care. Women may experience avoidable morbidity as a result of insufficient guidance or support following their surgeries. Consequently, it is imperative for medical education and training programs to incorporate comprehensive curricula that address not just the surgical procedures themselves but also the myriad repercussions that follow—for example, hormonal replacement therapy (HRT) options, lifestyle changes, and psychosocial support systems.

In cases where surgical menopause is deemed unavoidable, patients navigating this challenging transition should receive robust counseling regarding symptom management and long-term health risks. This involves not only discussing the trajectory of their menopause symptoms but also actively engaging them in understanding their heightened risk for osteoporosis and cardiovascular diseases. By educating women about signs to watch for and preventive measures to adopt, healthcare providers can empower patients to take control of their health outcomes during this turbulent time.

Additionally, implementing appropriate therapeutic strategies becomes not just a recommendation but a necessity. Hormonal treatments may often be relevant to alleviate the symptoms of menopause they will face after surgery. Yet, not all patients may choose or be suitable for hormonal replacement therapy, necessitating a diversified approach that also includes non-hormonal alternatives. This multiplicity of treatment options can be tailored to fit each patient’s unique health profile, preferences, and risk factors, ensuring that no one treatment strategy is over-applied without warranted consideration of the patient’s individual circumstances.

The psychological impact of undergoing radical cystectomy and dealing with post-operative menopause should also be factored into the comprehensive management of these patients. The emotional toll of battling cancer, combined with the psychological ramifications of surgical menopause, can lead to increased anxiety, depression, and diminished quality of life. Therefore, mental health support should be an integral component of any post-operative care plan.

Professional organizations and cancer care networks must prioritize the development of guidelines that specifically address the management of surgical menopause in women undergoing radical cystectomy. By establishing clear protocols and recommendations, we can ensure that every patient receives consistent and informed care, tailored to their specific needs and challenges. Furthermore, ongoing research is vital to enhance our understanding of how best to manage the long-term effects of surgical menopause, including the efficacy of various treatment methodologies that could be employed to mitigate risks and improve quality of life.

The collective goal is to create a paradigm shift in how healthcare providers view and treat female patients after radical cystectomy. As awareness grows, the emphasis will increasingly lean toward a patient-centered approach that underscores the importance of quality of life alongside cancer management. Ensuring that women are equipped with the knowledge and support they need can lead to healthier futures.

As the field continues to evolve, ongoing dialogue and education among health professionals will be essential. By fostering an environment where patient concerns are addressed, we ultimately aim to decrease the incidence of avoidable morbidity resulting from surgical menopause following radical cystectomy. A paradigm shift is necessary, one that places equal weight on both life-saving cancer treatments and the holistic management of a woman’s health throughout the course of treatment.

Expanding our understanding and treatment of surgical menopause is not only beneficial for patients but aligns with a broader movement within medicine towards integrative care models. Balancing oncological treatments with quality of life considerations signifies a progressive stance towards women’s health that acknowledges the complexities unique to female biology and the inevitable interplay between cancer treatment and hormone health. As research continues to unfold in this space, it promises to unlock new pathways for improving outcomes for these women.

In conclusion, the discussion surrounding the management of surgical menopause in female patients post-radical cystectomy is one that necessitates urgent attention and dedication. By collectively embracing this responsibility, we can advance the standard of patient care to reflect a commitment not only to survival but to the promotion of overall well-being in female cancer survivors.

Subject of Research: Management of surgical menopause in female patients undergoing radical cystectomy.

Article Title: Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.

Article References:

Day, E., Bizzarri, F.P., Mackenzie, C. et al. Management of surgical menopause in female patients with bladder cancer undergoing radical cystectomy.
Nat Rev Urol (2026). https://doi.org/10.1038/s41585-026-01124-z

Image Credits: AI Generated

DOI: 10.1038/s41585-026-01124-z

Keywords: radical cystectomy, surgical menopause, bladder cancer, women’s health, hormone therapy, cancer treatment, quality of life, oncological care.